November 25, 2024 Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer September 24, 2024 Oncology Pipeline Discovering and developing innovative therapies to deliver potentially transformative treatments ...
November 25, 2024 Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer September 24, 2024 Oncology Pipeline Discovering and developing innovative therapies to deliver potentially transformative treatments ...
September 24, 2024 Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer June 21, 2024 Oncology Pipeline Discovering and developing innovative therapies to deliver potentially transformative treatments ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda(TSE: 4502/NYSE:TAK)today announced that it will present data from its oncology pipeline and product portfolio at the60th Annual Meeting of the American Society of Clinical Oncology (ASCO)being held May 31-June 4, 2024, in Chicago, ...
November 25, 2024 Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer September 24, 2024 Oncology Pipeline Discovering and developing innovative therapies to deliver potentially transformative treatments ...
November 25, 2024 Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer September 24, 2024 Oncology Pipeline Discovering and developing innovative therapies to deliver potentially transformative treatments ...
November 25, 2024 Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer September 24, 2024 Oncology Pipeline Discovering and developing innovative therapies to deliver potentially transformative treatments ...
November 25, 2024 Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer September 24, 2024 Oncology Pipeline Discovering and developing innovative therapies to deliver potentially transformative treatments ...
November 25, 2024 Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer September 24, 2024 Oncology Pipeline Discovering and developing innovative therapies to deliver potentially transformative treatments ...
November 25, 2024 Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer September 24, 2024 Oncology Pipeline Discovering and developing innovative therapies to deliver potentially transformative treatments ...